Search

Your search keyword '"Arcaini, L"' showing total 595 results
Start Over Author "Arcaini, L"
595 results on '"Arcaini, L"'

1. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

Author

Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D’Sa, S., Eich, H.T., Foà, R., Ghia, P., da Silva, M.G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J.J., Kröger, N., Moreau, P., Passweg, J.R., Peyvandi, F., Rea, D., Ribera, J.-M., Robak, T., San-Miguel, J.F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., and Passamonti, F.

Published
2022
Full Text
View/download PDF

4. RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY

Author

Thieblemont, C., primary, Lamy, T., additional, Tani, M., additional, Krzisch, D., additional, Reda, G., additional, Tedeschi, A., additional, Usai, S. V., additional, Guarini, A., additional, Bijou, F., additional, Stathis, A., additional, Anastasia, A., additional, Devizzi, L., additional, Luminari, S., additional, Arcaini, L., additional, Casasnovas, O., additional, Gressin, R., additional, André, M., additional, Houot, R., additional, Bonomini, L., additional, Zucca, E., additional, and Conconi, A., additional

Published
2023
Full Text
View/download PDF

5. The Italian CART‐SIE real life multicenter observational study on Chimeric Antigen Receptor T‐cell (CAR‐T) therapy for large B‐cell (LBCL) and mantle cell (MCL) lymphomas

Author

Chiappella, A., primary, Dodero, A., additional, Ljevar, S., additional, Pennisi, M., additional, Bonifazi, F., additional, De Philippis, C., additional, Galli, E., additional, Di Rocco, A., additional, Tisi, M. C., additional, Cutini, I., additional, Carrabba, M. G., additional, Musso, M., additional, Martino, M., additional, Barbui, A. M., additional, Botto, B., additional, Farina, M., additional, Grillo, G., additional, Patriarca, F., additional, Ladetto, M., additional, Arcaini, L., additional, Bermema, A., additional, Miceli, R., additional, Magni, M., additional, Zinzani, P. L., additional, Bramanti, S., additional, Chiusolo, P., additional, Martelli, M., additional, Carniti, C., additional, and Corradini, P., additional

Published
2023
Full Text
View/download PDF

7. SARS-CoV-2 Infection in Patients with Waldenstrom's Macroglobulinemia: A Multicenter International Cohort Study

Author

Defrancesco, I., Ferretti, V. V., Morel, P., Kyriakou, C., Kastritis, E., Tohidi-Esfahani, I., Tedeschi, A., Buske, C., Garcia-Sanz, R., Vos, J. M. I., Peri, V., Margiotta Casaluci, G., Ferrari, A., Piazza, F., Oostvogels, R., Lovato, E., Montes, L., Fornecker, L. M., Grunenberg, A., Dimopoulos, M. A., Tam, C. S., D'Sa, S., Leblond, V., Trotman, J., Passamonti, F., Arcaini, L., and Varettoni, M.

Published
2023

8. Secreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms

Author

Pecquet, C, Papadopoulos, N, Balligand, T, Chachoua, I, Tisserand, A, Vertenoeil, G, Nédélec, A, Vertommen, D, Roy, A, Marty, C, Nivarthi, H, Defour, J-P, El-Khoury, M, Hug, E, Majoros, A, Xu, E, Zagrijtschuk, O, Fertig, TE, Marta, DS, Gisslinger, H, Gisslinger, B, Schalling, M, Casetti, I, Rumi, E, Pietra, D, Cavalloni, C, Arcaini, L, Cazzola, M, Komatsu, N, Kihara, Y, Sunami, Y, Edahiro, Y, Araki, M, Lesyk, R, Buxhofer-Ausch, V, Heibl, S, Pasquier, F, Havelange, V, Plo, I, Vainchenker, W, Kralovics, R, Constantinescu, SN, and UCL - SSS/DDUV/SIGN - Cell signalling

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Abstract

Mutant calreticulin (CALR) proteins resulting from a −1/+2 frameshifting mutation of the CALR exon 9 carry a novel C-terminal amino acid sequence and drive the development of myeloproliferative neoplasms (MPNs). Mutant CALRs were shown to interact with and activate the thrombopoietin receptor (TpoR/MPL) in the same cell. We report that mutant CALR proteins are secreted and can be found in patient plasma at levels up to 160 ng/mL, with a mean of 25.64 ng/mL. Plasma mutant CALR is found in complex with soluble transferrin receptor 1 (sTFR1) that acts as a carrier protein and increases mutant CALR half-life. Recombinant mutant CALR proteins bound and activated the TpoR in cell lines and primary megakaryocytic progenitors from patients with mutated CALR in which they drive thrombopoietin-independent colony formation. Importantly, the CALR-sTFR1 complex remains functional for TpoR activation. By bioluminescence resonance energy transfer assay, we show that mutant CALR proteins produced in 1 cell can specifically interact in trans with the TpoR on a target cell. In comparison with cells that only carry TpoR, cells that carry both TpoR and mutant CALR are hypersensitive to exogenous mutant CALR proteins and respond to levels of mutant CALR proteins similar to those in patient plasma. This is consistent with CALR-mutated cells that expose TpoR carrying immature N-linked sugars at the cell surface. Thus, secreted mutant CALR proteins will act more specifically on the MPN clone. In conclusion, a chaperone, CALR, can turn into a rogue cytokine through somatic mutation of its encoding gene.

Published
2022

9. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV

Author

Zappasodi P, Cattaneo C, Ferretti V, Mina R, Ferreri AJ, Merli F, Oberti M, Krampera M, Romano A, Zerbi C, Ferrari J, Cavo M, Marco Salvini M, Bertù L, Fracchiolla N, Marchesi F, Massaia M, Marasco V, Cairoli R, Scattolin AM, Vannucchi AM, Gambacorti-Passerini C, Musto P, Gherlinzoni F, Cuneo A, Pinto A, Trentin L, Bocchia M, Galimberti, Coviello E, Morotti A, Falini B, Turrin M, Tafuri A, Billio A, Gentile M, Lemoli M, Venditti A, Della Porta M, Lanza F, Rigacci L, Tosi P, Mohamed S, Corso A, Luppi M, Giuliani N, Busca A, Pagano L, Bruno R, Grossi P, Corradini P, Passamonti F, Arcaini L., Zappasodi, P, Cattaneo, C, Ferretti, V, Mina, R, Ferreri, A, Merli, F, Oberti, M, Krampera, M, Romano, A, Zerbi, C, Ferrari, J, Cavo, M, Marco Salvini, M, Bertù, L, Fracchiolla, N, Marchesi, F, Massaia, M, Marasco, V, Cairoli, R, Scattolin, A, Vannucchi, A, Gambacorti-Passerini, C, Musto, P, Gherlinzoni, F, Cuneo, A, Pinto, A, Trentin, L, Bocchia, M, Galimberti, Coviello, E, Mc, Morotti, A, Falini, B, Turrin, M, Tafuri, A, Billio, A, Gentile, M, Lemoli, M, Venditti, A, Della Porta, M, Lanza, F, Rigacci, L, Tosi, P, Mohamed, S, Corso, A, Luppi, M, Giuliani, N, Busca, A, Pagano, L, Bruno, R, Grossi, P, Corradini, P, Passamonti, F, Arcaini, L, Zappasodi, Patrizia, Cattaneo, Chiara, Ferretti, Virginia Valeria, Mina, Roberto, Ferreri, Andrés José María, Merli, Francesco, Oberti, Margherita, Krampera, Mauro, Romano, Alessandra, Zerbi, Caterina, Ferrari, Jacqueline, Cavo, Michele, Salvini, Marco, Bertù, Lorenza, Fracchiolla, Nicola Stefano, Marchesi, Francesco, Massaia, Massimo, Marasco, Vincenzo, Cairoli, Roberto, Scattolin, Anna Maria, Vannucchi, Alessandro Maria, Gambacorti-Passerini, Carlo, Musto, Pellegrino, Gherlinzoni, Filippo, Cuneo, Antonio, Pinto, Antonello, Trentin, Livio, Bocchia, Monica, Galimberti, Sara, Coviello, Elisa, Tisi, Maria Chiara, Morotti, Alessandro, Falini, Brunangelo, Turrini, Mauro, Tafuri, Agostino, Billio, Atto, Gentile, Massimo, Lemoli, Roberto Massimo, Venditti, Adriano, Della Porta, Matteo Giovanni, Lanza, Francesco, Rigacci, Luigi, Tosi, Patrizia, Mohamed, Sara, Corso, Alessandro, Luppi, Mario, Giuliani, Nicola, Busca, Alessandro, Pagano, Livio, Bruno, Raffaele, Grossi, Paolo Antonio, Corradini, Paolo, Passamonti, Francesco, and Arcaini, Luca

Subjects
Cancer Research, Lymphoma, Coinfection, COVID-19, Hematology, General Medicine, Settore MED/15, hematological malignancie, secondary infections, Settore MED/15 - MALATTIE DEL SANGUE, COVID-19 Testing, Oncology, Hematologic Neoplasms, secondary infection, outcome, Humans, hematological malignancies, Aged
Abstract

The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5-36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis.

Published
2022

10. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi

Author

Arcaini, L., Vallisa, D., Rattotti, S., Ferretti, V.V., Ferreri, A.J.M., Bernuzzi, P., Merli, M., Varettoni, M., Chiappella, A., Ambrosetti, A., Tucci, A., Rusconi, C., Visco, C., Spina, M., Cabras, G., Luminari, S., Tucci, M., Musto, P., Ladetto, M., Merli, F., Stelitano, C., d'Arco, A., Rigacci, L., Levis, A., Rossi, D., Spedini, P., Mancuso, S., Marino, D., Bruno, R., Baldini, L., and Pulsoni, A.

Published
2014
Full Text
View/download PDF

12. P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL.

Author

Ladetto, M., primary, Tavarozzi, R., additional, Evangelista, A., additional, Zanni, M., additional, Tucci, A., additional, Anastasia, A., additional, Botto, B., additional, Boccomini, C., additional, Bolis, S., additional, Volpetti, S., additional, Zilioli, V. R., additional, Puccini, B., additional, Arcari, A., additional, Pavone, V., additional, Gaidano, G., additional, Corradini, P., additional, Tani, M., additional, Ferrero, S., additional, Cavallo, F., additional, Milone, G., additional, Ghiggi, C., additional, Pinto, A., additional, Pastore, D., additional, Ferreri, A. J., additional, Latte, G., additional, Patti, C., additional, Re, F., additional, Arcaini, L., additional, Benedetti, F., additional, Usai, S. V., additional, Luminari, S., additional, Mannina, D., additional, Pulsoni, A., additional, Stelitano, C., additional, Pennese, E., additional, Pietrantuono, G., additional, Gherlinzoni, F., additional, Pomponi, F., additional, Olivieri, A., additional, Perrone, T., additional, Rota Scalabrini, D., additional, Califano, C., additional, Falini, B., additional, Ciccone, G., additional, and Vitolo, U., additional

Published
2022
Full Text
View/download PDF

13. P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL

Author

Zinzani, P. L., primary, Ansell, S. M., additional, Bosch, F., additional, Friedberg, J. W., additional, Marolleau, J. P., additional, Arcaini, L., additional, Garcia-Sanz, R., additional, Gopal, A. K., additional, Grande, C., additional, Merryman, R., additional, Pinto, A., additional, Smith, S. D., additional, Villasboas, J. C., additional, Wallace, D., additional, Fagerberg, J., additional, Magalhaes, J. G., additional, and Armand, P., additional

Published
2022
Full Text
View/download PDF

15. P1292: MOLECULAR CHARACTERIZATION OF DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED TO HEPATITIS C VIRUS INFECTION

Author

Sciarra, R., primary, Merli, M., additional, Cristinelli, C., additional, Lucioni, M., additional, Zibellini, S., additional, Riboni, R., additional, Uccella, S., additional, Furlan, D., additional, Zerbi, C., additional, Bianchi, B., additional, Gotti, M., additional, Ferretti, V. V., additional, Varraso, C., additional, Fraticelli, S., additional, Lazic, T., additional, Defrancesco, I., additional, Frigeni, M., additional, Mora, B., additional, Libera, L., additional, Bonfichi, M., additional, Sessa, F., additional, Passamonti, F., additional, Paulli, M., additional, and Arcaini, L., additional

Published
2022
Full Text
View/download PDF

16. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

Author

Buske, C. Dreyling, M. Alvarez-Larrán, A. Apperley, J. Arcaini, L. Besson, C. Bullinger, L. Corradini, P. Giovanni Della Porta, M. Dimopoulos, M. D'Sa, S. Eich, H.T. Foà, R. Ghia, P. da Silva, M.G. Gribben, J. Hajek, R. Harrison, C. Heuser, M. Kiesewetter, B. Kiladjian, J.J. Kröger, N. Moreau, P. Passweg, J.R. Peyvandi, F. Rea, D. Ribera, J.-M. Robak, T. San-Miguel, J.F. Santini, V. Sanz, G. Sonneveld, P. von Lilienfeld-Toal, M. Wendtner, C. Pentheroudakis, G. Passamonti, F.

Abstract

Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic. © 2022 The Authors

Published
2022

17. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Author

Passamonti, F, Cattaneo, C, Arcaini, L, Bruna, R, Cavo, M, Merli, F, Angelucci, E, Krampera, M, Cairoli, R, Della Porta MG, Fracchiolla, N, Ladetto, M, Gambacorti Passerini, C, Salvini, M, Marchetti, M, Lemoli, R, Molteni, A, Busca, A, Cuneo, A, Romano, A, Giuliani, N, Galimberti, S, Corso, A, Morotti, A, Falini, B, Billio, A, Gherlinzoni, F, Visani, G, Tisi, Mc, Tafuri, A, Tosi, P, Lanza, F, Massaia, M, Turrini, M, Ferrara, F, Gurrieri, C, Vallisa, D, Martelli, M, Derenzini, E, Guarini, A, Conconi, A, Cuccaro, A, Cudillo, L, Russo, D, Ciambelli, F, Scattolin, Am, Luppi, M, Selleri, C, Ortu La Barbera, E, Ferrandina, C, Di Renzo, N, Olivieri, A, Bocchia, M, Gentile, M, Marchesi, F, Musto, P, Federici, Ab, Candoni, A, Venditti, A, Fava, C, Pinto, A, Galieni, P, Rigacci, L, Armiento, D, Pane, F, Oberti, M, Zappasodi, P, Visco, C, Franchi, M, Grossi, Pa, Bertù, L, Corrao, G, Pagano, L, Corradini, P, ITA-HEMA-COV, Investigators., Passamonti, F., Cattaneo, C., Arcaini, L., Bruna, R., Cavo, M., Merli, F., Angelucci, E., Krampera, M., Cairoli, R., Della Porta, M. G., Fracchiolla, N., Ladetto, M., Gambacorti Passerini, C., Salvini, M., Marchetti, M., Lemoli, R., Molteni, A., Busca, A., Cuneo, A., Romano, A., Giuliani, N., Galimberti, S., Corso, A., Morotti, A., Falini, B., Billio, A., Gherlinzoni, F., Visani, G., Tisi, M. C., Tafuri, A., Tosi, P., Lanza, F., Massaia, M., Turrini, M., Ferrara, F., Gurrieri, C., Vallisa, D., Martelli, M., Derenzini, E., Guarini, A., Conconi, A., Cuccaro, A., Cudillo, L., Russo, D., Ciambelli, F., Scattolin, A. M., Luppi, M., Selleri, C., Ortu La Barbera, E., Ferrandina, C., Di Renzo, N., Olivieri, A., Bocchia, M., Gentile, M., Marchesi, F., Musto, P., Federici, A. B., Candoni, A., Venditti, A., Fava, C., Pinto, A., Galieni, P., Rigacci, L., Armiento, D., Pane, F., Oberti, M., Zappasodi, P., Visco, C., Franchi, M., Grossi, P. A., Bertu, L., Corrao, G., Pagano, L., Corradini, P., Passamonti F., Cattaneo C., Arcaini L., Bruna R., Cavo M., Merli F., Angelucci E., Krampera M., Cairoli R., Della Porta M.G., Fracchiolla N., Ladetto M., Gambacorti Passerini C., Salvini M., Marchetti M., Lemoli R., Molteni A., Busca A., Cuneo A., Romano A., Giuliani N., Galimberti S., Corso A., Morotti A., Falini B., Billio A., Gherlinzoni F., Visani G., Tisi M.C., Tafuri A., Tosi P., Lanza F., Massaia M., Turrini M., Ferrara F., Gurrieri C., Vallisa D., Martelli M., Derenzini E., Guarini A., Conconi A., Cuccaro A., Cudillo L., Russo D., Ciambelli F., Scattolin A.M., Luppi M., Selleri C., Ortu La Barbera E., Ferrandina C., Di Renzo N., Olivieri A., Bocchia M., Gentile M., Marchesi F., Musto P., Federici A.B., Candoni A., Venditti A., Fava C., Pinto A., Galieni P., Rigacci L., Armiento D., Pane F., Oberti M., Zappasodi P., Visco C., Franchi M., Grossi P.A., Bertu L., Corrao G., Pagano L., Corradini P., Passamonti, F, Cattaneo, C, Arcaini, L, Bruna, R, Cavo, M, Merli, F, Angelucci, E, Krampera, M, Cairoli, R, Della Porta, M, Fracchiolla, N, Ladetto, M, Gambacorti Passerini, C, Salvini, M, Marchetti, M, Lemoli, R, Molteni, A, Busca, A, Cuneo, A, Romano, A, Giuliani, N, Galimberti, S, Corso, A, Morotti, A, Falini, B, Billio, A, Gherlinzoni, F, Visani, G, Tisi, M, Tafuri, A, Tosi, P, Lanza, F, Massaia, M, Turrini, M, Ferrara, F, Gurrieri, C, Vallisa, D, Martelli, M, Derenzini, E, Guarini, A, Conconi, A, Cuccaro, A, Cudillo, L, Russo, D, Ciambelli, F, Scattolin, A, Luppi, M, Selleri, C, Ortu La Barbera, E, Ferrandina, C, Di Renzo, N, Olivieri, A, Bocchia, M, Gentile, M, Marchesi, F, Musto, P, Federici, A, Candoni, A, Venditti, A, Fava, C, Pinto, A, Galieni, P, Rigacci, L, Armiento, D, Pane, F, Oberti, M, Zappasodi, P, Visco, C, Franchi, M, Grossi, P, Bertu, L, Corrao, G, Pagano, L, and Corradini, P

Subjects
Male, Lymphoma, Comorbidity, 0302 clinical medicine, COVID-19, risk factors, death's rates, haematological malignancies, Retrospective Studie, Risk Factors, Neoplasms, 80 and over, haematological malignancies, Viral, Aged, 80 and over, education.field_of_study, Leukemia, Mortality rate, Lymphoma, Non-Hodgkin, Hazard ratio, Hematology, Plasma cell neoplasm, Middle Aged, Italy, 030220 oncology & carcinogenesis, Hematologic Neoplasms, Cohort, Plasma Cell, Female, Inpatient, Coronavirus Infections, Cohort study, Human, Adult, medicine.medical_specialty, Population, Pneumonia, Viral, Non-Hodgkin, Article, NO, Follow-Up Studie, 03 medical and health sciences, Betacoronavirus, Young Adult, COVID-19 haematological malignancies, Internal medicine, COVID-19, haematological malignancies, multicentre, retrospective, cohort study, Multivariable Cox, medicine, Humans, education, Hematologic Neoplasm, Neoplasms, Plasma Cell, Pandemics, Myeloproliferative Disorder, Aged, Retrospective Studies, Inpatients, Follow-Up Studies, Myeloproliferative Disorders, death's rates, Betacoronaviru, business.industry, Coronavirus Infection, SARS-CoV-2, Risk Factor, COVID-19, haematological malignancies, risk factors, COVID-19, Retrospective cohort study, Pneumonia, Settore MED/15, COVID-19 Drug Treatment, Settore MED/15 - MALATTIE DEL SANGUE, Standardized mortality ratio, business, 030215 immunology
Abstract

Summary Background Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance on COVID-19 aimed to collect data from adult patients with haematological malignancies who required hospitalisation for COVID-19. Methods This multicentre, retrospective, cohort study included adult patients (aged ≥18 years) with diagnosis of a WHO-defined haematological malignancy admitted to 66 Italian hospitals between Feb 25 and May 18, 2020, with laboratory-confirmed and symptomatic COVID-19. Data cutoff for this analysis was June 22, 2020. The primary outcome was mortality and evaluation of potential predictive parameters of mortality. We calculated standardised mortality ratios between observed death in the study cohort and expected death by applying stratum-specific mortality rates of the Italian population with COVID-19 and an Italian cohort of 31 993 patients with haematological malignancies without COVID-19 (data up to March 1, 2019). Multivariable Cox proportional hazards model was used to identify factors associated with overall survival. This study is registered with ClinicalTrials.gov , NCT04352556 , and the prospective part of the study is ongoing. Findings We enrolled 536 patients with a median follow-up of 20 days (IQR 10–34) at data cutoff, 85 (16%) of whom were managed as outpatients. 440 (98%) of 451 hospitalised patients completed their hospital course (were either discharged alive or died). 198 (37%) of 536 patients died. When compared with the general Italian population with COVID-19, the standardised mortality ratio was 2·04 (95% CI 1·77–2·34) in our whole study cohort and 3·72 (2·86–4·64) in individuals younger than 70 years. When compared with the non-COVID-19 cohort with haematological malignancies, the standardised mortality ratio was 41·3 (38·1–44·9). Older age (hazard ratio 1·03, 95% CI 1·01–1·05); progressive disease status (2·10, 1·41–3·12); diagnosis of acute myeloid leukaemia (3·49, 1·56–7·81), indolent non-Hodgin lymphoma (2·19, 1·07–4·48), aggressive non-Hodgkin lymphoma (2·56, 1·34–4·89), or plasma cell neoplasms (2·48, 1·31–4·69), and severe or critical COVID-19 (4·08, 2·73–6·09) were associated with worse overall survival. Interpretation This study adds to the evidence that patients with haematological malignancies have worse outcomes than both the general population with COVID-19 and patients with haematological malignancies without COVID-19. The high mortality among patients with haematological malignancies hospitalised with COVID-19 highlights the need for aggressive infection prevention strategies, at least until effective vaccination or treatment strategies are available. Funding Associazione italiana contro le leucemie, linfomi e mieloma–Varese Onlus.

Published
2020

24. A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPY.

Author

Davies, A. J., Zucca, E., Ceriani, L., Kryachok, I., Ciccone, G., Botto, B., Balzarotti, M., Tucci, A., Rusconi, C., Usai, S. V., Pennese, E., Arcaini, L., Dabrowska‐Iwanicka, A., Ferreri, A. J. M., Merli, F., Zhao, W., Hodgson, D., Rigacci, L., Cellini, C., and Stelitano, C.

Subjects
LYMPHOMAS
Abstract

The IELSG37 (NCT01599559) randomized trial was planned with a non-inferiority design to test whether RT can be omitted in PMBCL patients who achieve a complete metabolic response (CMR) after immunochemotherapy. Mediastinal radiotherapy (RT) may consolidate responses to dose-intensive immunochemotherapy; however, it increases the risk of second malignancies and coronary or valvular heart disease. B Introduction: b Primary mediastinal B-cell lymphoma (PMBCL) has a poor prognosis if remission is not rapidly achieved, or the disease recurs. [Extracted from the article]

Published
2023
Full Text
View/download PDF

25. PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT

Author

Ferreri, A. J.M., primary, Tarantino, V., additional, Cabras, G., additional, Ferrara, F., additional, Zinzani, P. L., additional, Arcaini, L., additional, Castellino, A., additional, Tucci, A., additional, Cocito, F., additional, Davies, A., additional, Salvador Chalup, M. M.B, additional, Cwynarski, K., additional, Nogueira, F. L., additional, Petrucci, L., additional, Muzi, C., additional, Onofrillo, D., additional, Ferrario, A., additional, Ramakrishnan, P., additional, Scalzulli, P. R., additional, Tani, M., additional, Tisi, M. C., additional, Papageorgiou, S. G., additional, Calimeri, T., additional, Angelillo, P., additional, Foppoli, M., additional, Dimou, M., additional, Ponzoni, M., additional, Iannitto, E., additional, and Vassilakopoulos, T. P., additional

Published
2021
Full Text
View/download PDF

26. RESPONSE ADAPTED POST INDUCTION THERAPY IN FOLLICULAR LYMPHOMA: UPDATED RESULTS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Luminari, S., primary, Galimberti, S., additional, Versari, A., additional, Tucci, A., additional, Boccomini, C., additional, Farina, L., additional, Zaja, F., additional, Marcheselli, L., additional, Ferrero, S., additional, Arcaini, L., additional, Pulsoni, A., additional, Musuraca, G., additional, Califano, C., additional, Merli, M., additional, Bari, A., additional, Conconi, A., additional, Giudice, I. del, additional, Re, F., additional, Stefani, P. M., additional, Usai, S. V., additional, Perrone, T., additional, Gini, G., additional, Falini, B., additional, Gattei, V., additional, Manni, M., additional, Ladetto, M., additional, Mannina, D., additional, and Federico, M., additional

Published
2021
Full Text
View/download PDF

27. IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL

Author

Martelli, M., primary, Zucca, E., additional, Botto, B., additional, Kryachok, I., additional, Ceriani, L., additional, Balzarotti, M., additional, Tucci, A., additional, Cabras, M. G., additional, Zilioli, V. R., additional, Rusconi, C., additional, Angrilli, F., additional, Arcaini, L., additional, Iwanicka, A. Dabrowska, additional, Ferreri, A.J.M., additional, Merli, F., additional, Zhao, W., additional, Hodgson, D., additional, Ionescu, C., additional, Fosså, A., additional, Cwynarski, K., additional, Mikhaeel, G., additional, Jerkeman, M., additional, Janikova, A., additional, Hüttmann, A., additional, Ciccone, G., additional, Metser, U., additional, Barrington, S., additional, Malkowski, B., additional, Versari, A., additional, Esposito, F., additional, Cozens, K., additional, Ielmini, N., additional, Ricardi, R., additional, Cavalli, F., additional, Johnson, P., additional, and Davies, A., additional

Published
2021
Full Text
View/download PDF

28. DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMI

Author

Merli, M., primary, Rattotti, S., additional, Spina, M., additional, Re, F., additional, Motta, M., additional, Piazza, F., additional, Orsucci, L., additional, Ferreri, Andrés J.M., additional, Perbellini, O., additional, Dodero, A., additional, Vallisa, D., additional, Pulsoni, A., additional, Santoro, A., additional, Zuccaro, V., additional, Chimienti, E., additional, Russo, F., additional, Visco, C., additional, Zignego, A. L., additional, Marcheselli, L., additional, Luminari, S., additional, Paulli, M., additional, Bruno, R., additional, and Arcaini, L., additional

Published
2021
Full Text
View/download PDF

29. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA

Author

Pulsoni, A., primary, Tosti, M. E., additional, Ferrero, S., additional, Luminari, S., additional, Dondi, A., additional, Liberati, A. M., additional, Cenfra, N., additional, Renzi, D., additional, Zanni, M., additional, Boccomini, C., additional, Ferreri, A. J., additional, Rattotti, S., additional, Zilioli, V. R., additional, Bernuzzi, P., additional, Bolis, S., additional, Musuraca, G., additional, Nassi, L., additional, Perrone, T., additional, Stelitano, C., additional, Anastasia, A., additional, Corradini, P., additional, Partesotti, G., additional, Re, F., additional, Cencini, E., additional, Mannarella, C., additional, Mannina, D., additional, Molinari, A. L., additional, Tani, M., additional, Annechini, G., additional, Assanto, G. M., additional, Grapulin, L., additional, Guarini, A., additional, Cavalli, M., additional, De Novi, L. A., additional, Ciabatti, E., additional, Mantoan, B., additional, Della Starza, I., additional, Arcaini, L., additional, Ricardi, U., additional, Gattei, V., additional, Galimberti, S., additional, Ladetto, M., additional, Foà, R., additional, and Del Giudice, I., additional

Published
2021
Full Text
View/download PDF

31. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA

Author

Bonfiglio, F., primary, Bruscaggin, A., additional, Guidetti, F., additional, Terzi di Bergamo, L., additional, Faderl, M., additional, Spina, V., additional, Condoluci, A., additional, Bonomini, L., additional, Forestieri, G., additional, Koch, R., additional, Piffaretti, D., additional, Pini, K., additional, Pirosa, M. C., additional, Cittone, M. G., additional, Arribas, A., additional, Lucioni, M., additional, Ghilardi, G., additional, Wu, W., additional, Arcaini, L., additional, Baptista, M. J., additional, Bastidas, G., additional, Bea, S., additional, Boldorini, R., additional, Broccoli, A., additional, Canzonieri, V., additional, Cascione, L., additional, Ceriani, L., additional, Cogliatti, S., additional, Derenzini, E., additional, Devizzi, L., additional, Dietrich, S., additional, Elia, A. R., additional, Facchetti, F., additional, Gaidano, G., additional, Garcia, J. F., additional, Gerber, B., additional, Ghia, P., additional, Silva, M. G., additional, Gritti, G., additional, Guidetti, A., additional, Hitz, F., additional, Inghirami, G., additional, Ladetto, M., additional, Lopez‐Guillermo, A., additional, Lucchini, E., additional, Maiorana, A., additional, Marasca, R., additional, Matutes, E., additional, Meignin, V., additional, Merli, M., additional, Moccia, A., additional, Mollejo, M., additional, Montalban, C., additional, Novak, U., additional, Oscier, D. G., additional, Passamonti, F., additional, Piazza, F., additional, Pizzolitto, S., additional, Sabattini, E., additional, Salles, G., additional, Santambrogio, E., additional, Scarfó, L., additional, Stathis, A., additional, Stüssi, G., additional, Geyer, J. T., additional, Tapia, G., additional, Thieblemont, C., additional, Tousseyn, T., additional, Tucci, A., additional, Visco, C., additional, Vitolo, U., additional, Zenz, T., additional, Zinzani, P. L., additional, Khiabanian, H., additional, Calcinotto, A., additional, Bertoni, F., additional, Bhagat, G., additional, Campo, E., additional, Leval, L., additional, Dirnhofer, S., additional, Pileri, S. A., additional, Piris, M. Án., additional, Traverse‐Glehen, A., additional, Tzankov, A., additional, Paulli, M., additional, Ponzoni, M., additional, Mazzucchelli, L., additional, Cavalli, F., additional, Zucca, E., additional, and Rossi, D., additional

Published
2021
Full Text
View/download PDF

37. The need to reappraise the definition of sarcopenia in cancer patients

Author

Cereda, E., primary, Lobascio, F., additional, Crotti, S., additional, Masi, S., additional, Cappello, S., additional, Turri, A., additional, Borioli, V., additional, Klersy, C., additional, Stobäus, N., additional, Tank, M., additional, Franz, K., additional, Cutti, S., additional, Arcaini, L., additional, Filippi, A.R., additional, Benazzo, M., additional, Palladini, G., additional, Pedrazzoli, P., additional, Norman, K., additional, and Caccialanza, R., additional

Published
2020
Full Text
View/download PDF

38. Importance of body composition in grading body mass index and weight loss-related nutritional risk in cancer patients

Author

Cereda, E., primary, Lobascio, F., additional, Masi, S., additional, Crotti, S., additional, Cappello, S., additional, Borioli, V., additional, Turri, A., additional, Klersy, C., additional, Stobäus, N., additional, Tank, M., additional, Franz, K., additional, Cutti, S., additional, Giaquinto, E., additional, Benazzo, M., additional, Filippi, A.R., additional, Arcaini, L., additional, Palladini, G., additional, Pedrazzoli, P., additional, Norman, K., additional, and Caccialanza, R., additional

Published
2020
Full Text
View/download PDF

41. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi

Author

Luminari, S., Biasoli, I., Arcaini, L., Versari, A., Rusconi, C., Merli, F., Spina, M., Ferreri, A. J. M., Zinzani, P. L., Gallamini, A., Mastronardi, S., Boccomini, C., Gaidano, G., DʼArco, A. M., Di Raimondo, F., Carella, A. M., Santoro, A., Musto, P., and Federico, M.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results